A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
This was a multicenter, open-label extension study. Patients who received vismodegib (GDC-0449) in a Genentech-sponsored study and who had completed the parent study or who continued to receive vismodegib at the time the parent study closed were eligible for continued treatment in this protocol.
Ovarian Cancer|Basal Cell Carcinoma|Metastatic Colorectal Cancer
DRUG: Vismodegib|DRUG: FOLFOX|DRUG: FOLFIRI|DRUG: Bevacizumab
Percentage of Participants Who Experienced at Least 1 Adverse Event, Baseline until 30 days following the last administration of study treatment|Percentage of Participants Who Discontinued Treatment Due to an Adverse Event, Baseline until 30 days following the last administration of study treatment
Incidence and Severity of All Adverse Events and Serious Adverse Events, 30 days following the last administration of study treatment|Incidence of Adverse Events Leading to GDC-0449 Discontinuation, 30 days following the last administration of study treatment
This was a multicenter, open-label extension study. Patients who received vismodegib (GDC-0449) in a Genentech-sponsored study and who had completed the parent study or who continued to receive vismodegib at the time the parent study closed were eligible for continued treatment in this protocol.